Pembrolizumab plus concurrent chemoradiotherapy demonstrated a higher progression-free survival rate than placebo plus ...

The combination of belrestotug and dostarlimab significantly improved response rates in patients with previously untreated ...

Median modified PFS was 9.4 months ... rashes. Withhold or permanently discontinue KEYTRUDA depending on severity.

Adding nogapendekin alfa inbakicept-pmln (N-803) to immune checkpoint inhibitor (ICI) therapy may overcome ICI resistance in patients with NSCLC.

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...

Antennova, a clinical-stage biotech company focused on oncology today announced that it presented the latest data of CD73 ...

Gilead Sciences, Inc. (Nasdaq: GILD) will present new data from the company’s broad lung cancer clinical development program during the IASLC 2024 World Conference on Lung Cancer hosted by the ...

Some patients with non-small cell lung cancer saw a 49% reduction in the risk of disease progression or death with ...

Detailed results from the TROPION-Lung01 Phase III trial showed a clinically meaningful trend toward improving overall survival (OS) with datopotamab ...

The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC ...

At WCLC, five-year survival data to be presented on Libtayo (PD-1 inhibitor) first-line monotherapy in advanced non-small cell lung cancerAt ...

Antennova, a clinical-stage biotech company focused on oncology today announced that it will present the latest data of CD73 ...